Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
25-Mar-2025 | 4,160 | 4,160 | 4,075 | 4,092.15 | 4,428 | 6,46,16,649.65 | 8,206 |
26-Mar-2025 | 4,093.5 | 4,120 | 3,997 | 4,010.1 | 7,496 | 12,10,45,138.55 | 19,129 |
27-Mar-2025 | 4,023 | 4,031 | 3,966 | 3,973.05 | 8,588 | 17,75,88,046.75 | 30,362 |
28-Mar-2025 | 3,970 | 4,104.9 | 3,954.65 | 4,004.5 | 11,188 | 23,17,61,859.35 | 30,185 |
01-Apr-2025 | 3,992.5 | 4,052.55 | 3,980 | 4,036.05 | 3,644 | 6,27,97,499.25 | 8,259 |
02-Apr-2025 | 4,055 | 4,058 | 3,975.55 | 4,047.35 | 3,980 | 5,53,58,436.9 | 6,410 |
03-Apr-2025 | 4,100 | 4,149.5 | 4,004.05 | 4,069.9 | 8,351 | 12,35,63,563.85 | 11,319 |
04-Apr-2025 | 4,069.85 | 4,069.85 | 3,955 | 4,017.3 | 6,513 | 10,43,09,137.65 | 14,443 |
07-Apr-2025 | 3,701 | 3,941.25 | 3,701 | 3,913.75 | 9,318 | 10,97,58,280.2 | 13,564 |
08-Apr-2025 | 3,990.85 | 4,033 | 3,894.3 | 4,023.7 | 5,248 | 8,36,82,191.5 | 11,295 |
09-Apr-2025 | 4,000 | 4,075.85 | 3,941.15 | 4,034.9 | 4,846 | 7,16,58,166.1 | 7,943 |
11-Apr-2025 | 4,115.6 | 4,115.6 | 4,001.2 | 4,080.25 | 6,402 | 8,09,14,821.15 | 10,249 |
15-Apr-2025 | 4,130 | 4,229.9 | 4,050 | 4,197.9 | 8,657 | 14,28,31,968.1 | 17,385 |
16-Apr-2025 | 4,204.5 | 4,214.1 | 4,164 | 4,201.8 | 4,876 | 6,15,17,712.4 | 7,392 |
17-Apr-2025 | 4,197 | 4,202.9 | 4,151 | 4,164.2 | 5,530 | 7,27,75,651.4 | 10,076 |
21-Apr-2025 | 4,165 | 4,199 | 4,125 | 4,191.4 | 5,396 | 8,89,18,657 | 10,223 |
22-Apr-2025 | 4,200 | 4,269.3 | 4,163.2 | 4,254.5 | 4,732 | 9,31,90,423.9 | 10,755 |
23-Apr-2025 | 4,267.8 | 4,268 | 4,179.6 | 4,243.5 | 4,730 | 6,72,51,333.1 | 8,184 |
Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.
The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.
Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24
At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
